News
Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was announced in May. Doustdar will assume the chief executive post on Aug. 7, a day after Novo reports its half-year performance, the company said Tuesday.
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...
Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert - The Danish firm blamed the move to slash its ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback